Author name: Leonardo Arias

New analysis from Jefferies shows that rare disease and cancer drugs granted the status are especially likely to be approved.

The insurer accused the health systems of putting business interests over patient well-being in recent failed contract negotiations.

  En el mundo digital, hay un encanto especial en tener documentos físicos. Sin embargo, los apuntes, borradores y notas que se acumulan con el tiempo suelen terminar en carpetas desordenadas, volviéndose difíciles de consultar y fáciles de perder. La soluci&oacut …

Adam Kautzner will oversee the PCMA’s strategy as chair of the board, including its defense of pharmacy benefit managers amid growing scrutiny of their role in rising drug costs.

Investment in 2025 has reached $9.9 billion, exceeding the $8.4 billion that was raised through the third quarter last year, according to Rock Health.

The sale will leave Owens & Minor focused on a smaller but potentially faster-growing and higher-margin business that provides products directly to patients.

Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.

The centerpiece of the deal is orelabrutinib, a BTK inhibitor in late-stage development for multiple sclerosis that Biogen once paid $125 million for but abandoned after less than two years of testing.

Executives from Stryker and Johnson & Johnson are on the hunt for deals, despite a turbulent environment, they said at AdvaMed’s The MedTech Conference.

At AdvaMed’s annual conference, CEO Scott Whitaker addressed policy issues around tariffs, FDA staff cuts and the ongoing government shutdown.